The 12-month price targets, analyzed by analysts, offer insights with an average target of $33.11, a high estimate of $68.00, ...

The stock's fall snapped a two-day winning streak.

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning ...

Regeneron Pharmaceuticals took a modest hit as BDF Gestion reduced its stake by 11.5% in the first quarter, now holding $2.8 ...

Pallas Capital Advisors jumped into the biotech game by purchasing $426,000 worth of Regeneron Pharmaceuticals shares during ...